April 27, 2020
TRiNDS is honored to work with clients from around the world working to develop investigational products for rare neuromuscular diseases. Today, one of our clients shared a press release about their progress.
Italfarmaco Group has issued a press release to provide an update on the clinical development program with Givinostat in Duchenne muscular dystrophy (DMD).
Paolo Bettica, MD, PhD, Chief Medical Officer at the Italfarmaco Group commented, “The interim data from our Phase 3 trial and the updated long – term study results with Givinostat are both very encouraging…Italfarmaco could close enrollment in the trial as early as July 2020 with the final analysis of the results expected in 2022.”
TRiNDS is a contract research organization (CRO) dedicated to conducting rare and neuromuscular disease research. We are currently accepting new clients developing products for rare disease and neuromuscular patient populations. Contact TRiNDS today to request a quote.